Related Experiment Video

Updated: Aug 7, 2026

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy

Ting-Ting Tan1, Kurt Degenhardt, Deirdre A Nelson

  • 1Center for Advanced Biotechnology and Medicine, Rutgers University, Piscataway, New Jersey 08854, USA.

Cancer Cell
|March 16, 2005
PubMed

Insights

The proapoptotic protein BIM acts as a tumor suppressor and influences paclitaxel sensitivity. Targeting the H-ras/MAPK pathway with Velcade can overcome resistance and enhance tumor regression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Death Research

Background:

  • Defective apoptosis (programmed cell death) is linked to cancer development and can hinder chemotherapy effectiveness.
  • The BH3-only protein BIM is a key regulator of apoptosis.
  • Paclitaxel is a widely used chemotherapy drug, but resistance can limit its efficacy.

Purpose of the Study:

  • To investigate the role of BIM in epithelial solid tumors and its impact on paclitaxel sensitivity.
  • To elucidate the mechanisms by which the H-ras/mitogen-activated protein kinase (MAPK) pathway confers resistance to paclitaxel.
  • To explore the therapeutic potential of combining a proteasome inhibitor with paclitaxel.

Main Methods:

  • In vitro and in vivo experiments were conducted using epithelial solid tumor models.
  • The study analyzed BIM accumulation, phosphorylation, and degradation.
  • The effects of paclitaxel, H-ras/MAPK pathway activation, and the proteasome inhibitor Velcade (Bortezomib) on BIM and tumor response were assessed.

Main Results:

  • BIM was identified as a tumor suppressor and a critical factor in paclitaxel sensitivity.
  • The H-ras/MAPK pathway promoted paclitaxel resistance by phosphorylating BIM, leading to its proteasomal degradation.
  • Paclitaxel treatment induced BIM accumulation and apoptosis, which was suppressed by the H-ras/MAPK pathway.
  • Velcade restored BIM induction, reversed H-ras-mediated paclitaxel resistance, and promoted tumor regression.

Conclusions:

  • BIM is a crucial mediator of apoptosis and a determinant of paclitaxel response in epithelial solid tumors.
  • The H-ras/MAPK pathway confers paclitaxel resistance through BIM inactivation.
  • Combining Velcade with paclitaxel shows promise for overcoming drug resistance and enhancing chemotherapeutic outcomes.

More Related Videos

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics12:28

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Published on: January 11, 2019

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...